AutoImmune, Inc. (AIMM) Release: Clinical Trial by Licensee Does Not Meet Primary Endpoint
7/31/2009 9:34:05 AM
PASADENA, Calif., July 30 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM - News) today announced its licensee, BioMS Medical Corp., and Eli Lilly and Company reported that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study. Lilly and BioMS also announced that they would discontinue ongoing clinical trials and review available data.
comments powered by